TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05859659

Intervention type: DIAGNOSTIC_TEST
Intervention: This study does not intervene in this process.
Description: This study does not intervene in this process.

Intervention type: DIAGNOSTIC_TEST
Intervention: This study does not intervene in this process.
Description: This study does not intervene in this process.
Study: NCT05116098

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: zinc 50 mg + Epigallocatechin gallate
Description: ZINC 50 MG and EGCG 200mg oral daily for 1 month

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: zinc 50 mg + Epigallocatechin gallate
Description: ZINC 50 MG and EGCG 200mg oral daily for 1 month
Study: NCT04867382

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Online training
Description: This intervention consisted of two different interactive online trainings delivered through an online learning platform at HealthPartners.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online training
Description: This intervention consisted of two different interactive online trainings delivered through an online learning platform at HealthPartners.
Study: NCT05832593

Intervention type: OTHER
Intervention: Immunohistochemistry
Description: Immunohistochemical expression of ERCC1

Intervention type: OTHER
Intervention: Immunohistochemistry
Description: Immunohistochemical expression of ERCC1
Study: NCT06509529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Based on the COM-B Model
Description: Motivational Interviewing Based on the COM-B Model will be applied to the women in the experimental group.
Study: NCT06423404

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: the Experimental Group, receiving a 12-week program of video-guided active breaks with curricular content in the school classroom
Description: The \&#34;Active Classes + School Climate and Mental Health\&#34; program was crafted following a comprehensive review by the research team on active breaks in the child school population. Based on the findings of this review, the optimal type and duration of intervention, frequency and intensity of the most effective exercises, and video-guided modalities with curricular content for active breaks will be established. Subsequently, a collaborative network was formed, involving researchers from education, sports science, social sciences, medicine, primary school teachers within the Chilean public school system, teams of educational leaders, parents, guardians, pedagogy students, and graduate students. The purpose was to create a team that systematically supports the development of various stages of the project from a multi and interdisciplinary perspective

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Experimental Group, receiving a 12-week program of video-guided active breaks with curricular content in the school classroom
Description: The \&#34;Active Classes + School Climate and Mental Health\&#34; program was crafted following a comprehensive review by the research team on active breaks in the child school population. Based on the findings of this review, the optimal type and duration of intervention, frequency and intensity of the most effective exercises, and video-guided modalities with curricular content for active breaks will be established. Subsequently, a collaborative network was formed, involving researchers from education, sports science, social sciences, medicine, primary school teachers within the Chilean public school system, teams of educational leaders, parents, guardians, pedagogy students, and graduate students. The purpose was to create a team that systematically supports the development of various stages of the project from a multi and interdisciplinary perspective
Study: NCT06041230

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ozone Generator
Description: Ultrasound guided ozone therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy device
Description: Extracorporeal shock wave therapy device
Study: NCT05015062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-based HIV-related educational message delivery
Description: HIV/AIDS awareness-raising and behavior-related cyclic messages will be delivered by the village doctors on a biweekly basis for 18 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile-based HIV-related educational message delivery
Description: HIV/AIDS awareness-raising and behavior-related cyclic messages will be delivered by the village doctors on a biweekly basis for 18 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive policies evaluation
Description: village doctors in Intervention A and B will receive different types of monetary compensation. Doctors in Intervention A will receive standardized compensation for completing their assigned tasks. Doctors in Intervention B will receive performance-based compensation whose amount depends on how well the participants perform on the follow-up questionnaires.
Study: NCT04093401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individualized risk assessment
Description: Individualized risk assessment of developing a second basal cell carcinoma
Study: NCT05043194

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ursodeoxycholic Acid 250 Mg Oral Capsule
Description: prevention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid 250 Mg Oral Capsule
Description: prevention
Study: NCT05656131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Arms A will be treated with fluzoparib alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib+Camrelizumab
Description: Arms B will be treated with fluzoparib in combination with camrelizumab
Study: NCT05763329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1
Description: Patients will receive Lemborexant 5 mg per day on the first day of sleep test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2
Description: Patients will receive Lemborexant 5 mg per day on the second day of sleep test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Day 1
Description: Patients will receive placebo on the first day of sleep test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Day 2
Description: Patients will receive placebo on the second day of sleep test
Study: NCT06233552

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional denture conversion
Description: conventional workflow usually done to do immediate loading for full arch implant cases

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: digital denture conversion
Description: An alternative workflow for construction of the fixed interim requires impressions, model production, and jaw relation records then digitizing all these data then designing and milling the restoration.
Study: NCT06437886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: opioid-sparing protocol
Description: Patients in the OSA group was administrated with 0.5 to 1 mcg·kg-1 sufentanil and received PIFB combined with RSB after anesthetic induction. Patients in the control group were recommended to receive 2 to 3 mcg·kg-1 opioid-based sufentanil. PIFB was conducted at the T2 to T5 levels under ultrasound guidance. Each side received 20 ml 0.3% ropivacaine containing 2.5 mg dexamethasone. Bilateral RSB was conducted after the PIFB and the needle was inserted into the plane between the rectus abdominal muscle and its posterior sheath using an in-plane approach. After verifying needle placement, 15 ml 0.3% ropivacaine containing 2.5 mg dexamethasone was delivered to each side. In the control group, patients received no procedure and were administrated with traditional anesthetic protocol. Patients received continuous intravenous sufentanil (50 to 100 mg) and tropisetron (5 to 10 mg) at 2 ml·h-1 for the first 48 hours after surgery.
Study: NCT05864131

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lying
Description: After the urethral catheter is inserted, the participant lies on an examination table lined with paper towels and diapers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holding
Description: Holding is performed as a non-pharmacological intervention to relieve pain in children during cystometry. After the urethral catheter is inserted, the participant's parent sits in the chair, placing a paper towel and diaper on their lap. The researcher lifts the participant by the shoulder and puts them on their parent's lap, and the parent holds the participant in their arms.
Study: NCT05543018

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electroretinogram
Description: Retinal function assessment using electroretinogram

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electroretinogram
Description: Retinal function assessment using electroretinogram

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Electroretinogram
Description: Retinal function assessment using electroretinogram

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy operation
Description: Vitrectomy operation to treat retinal detachment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy operation
Description: Vitrectomy operation to treat retinal detachment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy operation
Description: Vitrectomy operation to treat retinal detachment
Study: NCT06360081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zongertinib
Description: Zongertinib
Study: NCT04580277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Description: Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks
Study: NCT05079633

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Homologous boost schedule
Description: 1st dose mRNA 1273 , 2nd dose mRNA 1273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heterologous boost schedule
Description: 1st dose mRNA 1273 , 2nd dose MVC COV1901
Study: NCT05162469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1909 injection
Description: SHR-1909 for intravenous injection;Strength:6ml:0.3g/vial. Dose escalation (non randomized, 6 dose-levels); Dose-expansion and efficacy-expansion(non-randomized,1-3 dose-level(s)).
Study: NCT04522193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glycemic Holter
Description: Continuous glycaemia monitoring,

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gastric emptying scintigraphy
Description: Fasting administration of a Technecium-labelled milk bottle and quantification of the remaining radioactivity by a camera every 30 minutes for 4 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter ECG
Description: continuous cardiac monitoring
Study: NCT04834375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weight-based dexamethasone dose
Description: Weight-based dexamethasone dose in COVID-19 patients with hypoxic respiratory failure
Study: NCT04144933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen, Gabapentin
Description: 975 mg, 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen, Gabapentin
Description: 975 mg, 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution, Dexmedetomidine, Ketamine
Description: 1.5 mg/kg, 0.5 mcg/kg, 0.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, Ondansetron
Description: 6 mg, 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, Ondansetron
Description: 6 mg, 4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane, Lidocaine 2% Injectable Solution, Ketamine, Dexmedetomidine, Magnesium Sulfate
Description: Dose titrated to effect, 1.5 mg/kg/hr, 0.15 mg/kg/hr, 0.3 -1 mcg/kg/hr (titrated to effect), 30 mg/kg bolus over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1% Injectable Solution, Sufentanil
Description: 0.5 mg/kg, 0.25-0.5 mcg/kg (titrated to effect)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane, Sufentanil
Description: Dose titrated to effect, As needed (dose at anesthesiologist's discretion)
Study: NCT05907083

Intervention type: RADIATION
Intervention: cone beam computer tomography
Description: Cone Beam CT Radiation
Study: NCT05257915

Intervention type: DRUG
Intervention: Perampanel
Description: For patients ≥12 years old, the initial dose is 2 mg/d, and according to the clinical response and tolerance of the patient, the dose is increased to the minimum clinically effective dose in increments of 2 mg, and the interval between dose increases is not less than 2 weeks.~For patients \<12 years, according to the actual clinical situation, the initial dose and addition plan are judged by the investigator.
Study: NCT05569915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Expressive Writing
Description: Participants assigned to the trauma condition will write about an experience of trauma for 15 to 20 minutes per day across five consecutive days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma Expressive Writing
Description: Participants assigned to the stigma condition will write about an experience of stigma or bias for 15 to 20 minutes per day across five consecutive days.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants assigned to the control condition will write about their days for 15 to 20 minutes per day across five consecutive days. This control condition is standard across many expressive writing studies.
Study: NCT05705960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chestnut
Description: Daily consumption of roasted chestnut (150g) for 14 days
Study: NCT05071794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Antiemetic effect of propofol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9%
Description: Placebo
Study: NCT06028893

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heart rhythm measurements with FibriCheck®
Description: Measurements are performed twice daily, starting 4 weeks before a pulmonary vein isolation procedure (PVI) and ending 4 weeks after the PVI.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heart rhythm measurements with Kardia Mobile®
Description: Measurements are performed immediately before and after every FibriCheck® measurement.
Study: NCT05543343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose or normal dose staphylococcus albicans
Description: 8 staphylococcus albicans tablets(0.3 mg) 3 times daily or 4 staphylococcus albicans tablets(0.3 mg)+4 placebo tablets 3 times daily
Study: NCT05301426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching of the hamstring muscles.
Description: Passive stretching of the hamstring muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural slippage of the sciatic nerve.
Description: Neurodynamic technique on the sciatic nerve.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive upper limb mobilisations.
Description: Passive mobilisations performed on the upper limbs used as a placebo.
Study: NCT05543343

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 placebo tablets 3 times daily
Study: NCT05969717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GD-iExo-001
Description: One drop (about 50 μL) of GD-iExo-001 was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: One drop (about 50 μL) of normal saline was given to the affected skin area of 2-4 cm2 for 14 consecutive days, twice per day.
Study: NCT05102617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoSure Pro Device
Description: This device will be used for up to 4 treatments over the designated areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoSure Pro Device
Description: This device will be used for up to 4 treatments over the designated areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoSure Pro Device
Description: This device will be used for up to 4 treatments over the designated areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoSure Device
Description: This device will be used for up to 4 treatments over the designated areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoSure Device
Description: This device will be used for up to 4 treatments over the designated areas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoSure Device
Description: This device will be used for up to 4 treatments over the designated areas.
Study: NCT04784390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Binocular video games
Description: Patients will play 1 hour of binocular video game of choice (Dig Rush and/or Monster Burner) a day 7 days a week for 8 to 12 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching of the sound eye
Description: Patients will have their sound eye (fellow eye) patched 2 hours per day 7 days a week for 16 weeks.
Study: NCT06084546

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: geko™ X-W3
Description: The geko™ X-W3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ W3 device and the new geko™ XW-3 device is the adhesive used to attach each device to the skin.
Study: NCT06493396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid-free Analgesics
Description: opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid group
Description: Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
Study: NCT04658667

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (Sodium Chloride for injection USP, 0.9%) will be used as placebo.
Study: NCT06207981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction chemotherapy (mDCF)
Description: Induction chemotherapy consists of mDCF administered every 2 weeks:~* Docetaxel (40 mg/m², day 1),~* Cisplatin (40 mg/m², day 1)~* 5-FU (1200 mg/m²/day IV for 2 days)
Study: NCT05102617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Cosmeceuticals
Description: Topical cosmeceuticals, such as a hydrating serum or cream, will be applied on the designated area.
Study: NCT04801888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.
Description: The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.
Study: NCT05067920

Intervention type: DIAGNOSTIC_TEST
Intervention: Levels of SARS-COV-2 antibodies
Description: Study of the SARS-COV-2 antibodies of COVID-19 IgM ( day 5th and 14th) and IgG ( day 14th and 28th)

Intervention type: DIAGNOSTIC_TEST
Intervention: Levels of SARS-COV-2 antibodies
Description: Study of the SARS-COV-2 antibodies of COVID-19 IgM ( day 5th and 14th) and IgG ( day 14th and 28th)

Intervention type: DIAGNOSTIC_TEST
Intervention: rRT-PCR SARS-Cov-2
Description: Real time RT-PCR for COVID-19 diagnosis at day 5th,14th and 28th

Intervention type: DIAGNOSTIC_TEST
Intervention: rRT-PCR SARS-Cov-2
Description: Real time RT-PCR for COVID-19 diagnosis at day 5th,14th and 28th

Intervention type: DIAGNOSTIC_TEST
Intervention: Hematological and immunological biomarkers
Description: Laboratory data measure at day 5th,14th and 28th: Hemogram, cytokine levels, ratio of CD4 + / CD8 + lymphocytes, and levels of dehydrogenase lactate, ferritin, D-dimer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hematological and immunological biomarkers
Description: Laboratory data measure at day 5th,14th and 28th: Hemogram, cytokine levels, ratio of CD4 + / CD8 + lymphocytes, and levels of dehydrogenase lactate, ferritin, D-dimer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Mitochondrial DNA
Description: One time quantification mitochondrial DNA haplogroup.

Intervention type: DIAGNOSTIC_TEST
Intervention: Mitochondrial DNA
Description: One time quantification mitochondrial DNA haplogroup.

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 Viral Culturing
Description: Probability of isolating SARS-Cov-2 in cell culture related to CT value above 32.

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 Viral Culturing
Description: Probability of isolating SARS-Cov-2 in cell culture related to CT value above 32.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sequencing COVID-19
Description: Sequencing viral protein spike (S) COVID-19 related to CT value below 15.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sequencing COVID-19
Description: Sequencing viral protein spike (S) COVID-19 related to CT value below 15.